Last updated: July 27, 2026
Encorafenib (Braftovi) is a BRAF-targeted therapy used in BRAF V600–mutant melanoma and, in combination, in metastatic colorectal cancer (mCRC). Clinical development continues to expand the regimen into earlier lines and additional tumor contexts, while the commercial outlook depends on ongoing label penetration versus forecast competitive pressure from other BRAF/EGFR strategies and broader MEK inhibition approaches.
Encorafenib clinical trials update: what studies are driving the pipeline?
Featured snapshot: Encorafenib’s highest-impact clinical efforts cluster in (1) melanoma expansion by line of therapy and regimen refinements and (2) mCRC combinations built around EGFR inhibition and disease-stage settings.
What are the key clinical trial programs for encorafenib?
The pivotal and post-pivotal trial base centers on two anchor combinations:
- Encorafenib + binimetinib (BRAF V600E/K melanoma and related indications)
- Encorafenib + cetuximab (BRAF V600E/K metastatic colorectal cancer)
Current expansion efforts are typically structured around:
- earlier-stage settings (neoadjuvant/adjuvant concepts or earlier-line metastatic settings)
- treatment sequencing questions (first-line vs subsequent lines)
- overcoming resistance phenotypes (broadening combinations beyond the base EGFR + MEK backbone)
- exploring tumor-agnostic biomarker strategies where BRAF V600 mutations occur
Which tumor types are seeing the most encorafenib trial activity?
- Melanoma: BRAF V600E/K–mutant disease, focusing on line-of-therapy positioning and combination optimization with MEK inhibition.
- Metastatic colorectal cancer: BRAF V600E–mutant disease in combination with anti-EGFR therapy.
- Other solid tumors: trials based on BRAF V600 mutation presence, including studies in rarer biomarker-defined cohorts.
What endpoints and regulatory signals matter most in encorafenib trials?
High commercial and regulatory relevance usually comes from:
- Overall survival (OS) and progression-free survival (PFS) in registration-enabling settings
- ORR and duration of response (DoR) as accelerant signals in biomarker-selected cohorts
- safety/tolerability that supports chronic combination dosing (cardiac monitoring, ocular effects, dermatologic toxicity, and lab abnormalities)
No complete, source-verifiable list of currently active encorafenib trials and readouts is provided here because the request requires exact trial-by-trial updating (phase, NCT, enrollment, last update, and results) which cannot be produced accurately without direct access to current clinicaltrials.gov or equivalent registries.
Encorafenib market analysis: what is the current commercial footprint and growth outlook?
Featured snapshot: Encorafenib’s market is anchored by its combination role in melanoma and mCRC, with growth driven by label penetration and sequencing, while offset by payer scrutiny and competitive choices in the BRAF inhibitor class and anti-EGFR strategies.
Where does encorafenib revenue come from?
Commercial revenue is primarily tied to:
- Braftovi (encorafenib) + binimetinib regimens in melanoma
- Braftovi + cetuximab regimens in BRAF V600–mutant metastatic colorectal cancer
The mix between melanoma and mCRC depends on:
- epidemiology (incidence of BRAF V600E/K in each tumor)
- first-line versus later-line uptake patterns
- affordability and reimbursement dynamics for combination regimens
How does competitive pressure shape encorafenib pricing and uptake?
Key competitive pressures typically include:
- other BRAF/MEK and BRAF/EGFR combination strategies that may offer similar efficacy with different safety or convenience
- anti-EGFR backbone evolution in CRC (biomarker selection, resistance mechanisms, and sequencing with chemotherapy or immunotherapy)
- payer use of substitution lists based on budget impact and comparative effectiveness evidence
What market risks matter for encorafenib?
Commercial sensitivity points include:
- biomarker stratification (BRAF V600E/K prevalence and test behavior)
- sequencing changes where new regimens displace current standards
- safety management costs from chronic combination dosing
- patent/litigation outcomes affecting generic availability of encorafenib formulations or combination components in relevant jurisdictions (US/EU/JP)
No numeric market sizing, year-by-year revenue figures, or projection ranges are included because the request requires quantified forecasts and historicals. Those numbers must be sourced from current market research or company disclosures; providing numbers without source-backed citations would violate accuracy requirements.
When does encorafenib lose exclusivity and what generic entry risks exist?
Featured snapshot: Exclusivity and patent expiry timelines determine the speed of generic or biosimilar substitution for encorafenib products (small molecule), with the practical launch window shaped by Orange Book listings and any Paragraph IV litigation or settlements.
What patents protect encorafenib in the US?
The US exclusivity landscape is determined by:
- the Orange Book drug listings for encorafenib (Braftovi) and combination-relevant formulations
- listed composition-of-matter, formulation, and method-of-use patents
- any terminal disclaimers
- any patent litigation affecting launch timing
A complete and accurate patent-by-patent exclusivity chart (numbers, expiry dates, continuation status, and legal status) is not provided because the underlying Orange Book and litigation record is not provided in the prompt, and producing it without verified listings would risk errors.
Do Paragraph IV challenges threaten encorafenib before patent expiry?
Paragraph IV risk depends on:
- whether ANDA filers are tied to specific Orange Book patents
- whether litigation leads to automatic stays or earlier settlement dates
- whether final FDA approval timelines compress market entry
No Paragraph IV case-specific details are included for the same reason: exact docket status and settlement terms require docket-accurate sourcing.
Encorafenib FDA status: what is approved and how do regulators affect the label?
Featured snapshot: Encorafenib’s regulatory position rests on combination approvals in melanoma and metastatic colorectal cancer. Expansion depends on submission strategy, trial endpoints, and whether confirmatory evidence supports durable benefit.
What are the key approved encorafenib combinations?
- Encorafenib + binimetinib for BRAF V600 mutation–positive melanoma (as approved)
- Encorafenib + cetuximab for BRAF V600 mutation–positive metastatic colorectal cancer (as approved)
How does FDA labeling constrain or enable new trials?
Labeling influences:
- line-of-therapy positioning for new combinations
- eligibility criteria for clinical cohorts (often aligned to label biomarker requirements)
- how sponsors design endpoints for expansion submissions
A statement-by-statement label mapping (indication, line, biomarker test, and dose) is not included because exact FDA label text is not supplied and must be validated for accuracy.
Encorafenib vs dabrafenib/trametinib and other BRAF strategies: how does efficacy and safety compare?
Featured snapshot: Encorafenib competes in the BRAF inhibitor class through combination strategy design (BRAF + MEK and, separately, BRAF + EGFR). Comparative positioning depends on OS/PFS balance, toxicity management, and sequencing.
What is the competitive differentiator profile for encorafenib?
Common differentiation levers include:
- survival benefit magnitude and durability in BRAF V600–mutant cohorts
- safety profile enabling sustained dosing
- combination simplicity versus alternative triple strategies
- resistance management and cross-trial interpretability
No direct head-to-head table is provided because comparative efficacy needs citation to trial publications and label-level dosing, which is not included in the prompt.
Encorafenib commercialization projection: what growth scenarios are most likely?
Featured snapshot: The most likely commercial trajectory is scenario-based, with growth driven by label expansion and sequencing capture, and downside driven by competitive substitution and payer restrictions.
Base-case scenario drivers
- increased testing and treatment identification for BRAF V600 mutations
- regimen adherence and payer acceptance for combination therapy
- incremental uptake in earlier-line metastatic settings if supported by trial results
Downside scenario drivers
- intensified competition from alternative BRAF/MEK and BRAF/EGFR regimens
- label constraints or insufficient confirmatory readouts for any expansion
- payer-driven restrictions for combination cost-effectiveness
Upside scenario drivers
- label expansion into additional biomarker-defined indications
- stronger-than-expected durability metrics that improve sequencing adoption
- favorable safety profile that reduces dose interruptions
No year-by-year projection numbers are included because they require numeric assumptions tied to sourced inputs (market size, share, pricing, and competitive dynamics).
Key takeaways
- Encorafenib’s core market is built on two combination pillars: encorafenib + binimetinib (melanoma) and encorafenib + cetuximab (BRAF V600E metastatic colorectal cancer).
- Clinical development is expected to prioritize earlier lines, biomarker-enriched populations, and resistance-oriented combinations, with readouts that could expand label positioning.
- Commercial outlook is most sensitive to sequencing, payer acceptance, and competition in BRAF-targeted strategies, plus exclusivity and launch timing for generic encorafenib.
- A complete, litigation-grade view of exclusivity and a quantified market forecast require Orange Book and market data that are not included in the prompt.
FAQs
- How many clinical trials for encorafenib are currently recruiting by phase and tumor type?
- What is the Orange Book status for Braftovi (encorafenib) and when do listed patents expire?
- Are there any active Paragraph IV ANDA cases challenging encorafenib, and what are their litigation timelines?
- What dosing regimen is used for encorafenib combinations in melanoma and metastatic colorectal cancer, and how do dose modifications affect real-world use?
- How does encorafenib’s market share trend in metastatic colorectal cancer versus melanoma?
References
- (No citable source list provided because the prompt does not include verifiable inputs and the response cannot meet citation requirements without external registry and commercial data.)
